Childhood Cancer Incidence, New York City, 2016-2020

Source: New York State Cancer Registry

Site of Cancer Ages 0-4 Ages 5-9 Ages 10-14 Ages 15-19 Combined Ages 0-14 Combined Ages 0-19
Avg Annual Cases Rate per 1,000,000 Avg Annual Cases Rate per 1,000,000 Avg Annual Cases Rate per 1,000,000 Avg Annual Cases Rate per 1,000,000 Avg Annual Cases Rate per 1,000,000 95% CI Avg Annual Cases Rate per 1,000,000 95% CI
All Invasive Malignant Tumors 129.2 241.5 69.8 143.8 87.2 194.2 131.6 296.7 286.2 192.3 182.4-202.5 417.8 218.5 209.2-228.1
I Leukemias, myeloproliferative and myelodysplastic diseases 42.2 78.9 20.6 42.4 20.6 45.9 24.4 55.0 83.4 55.4 50.2-61.1 107.8 55.3 50.7-60.2
   I(a) Lymphoid leukemias 29.2 54.6 16.8 34.6 12.8 28.5 14.0 31.6 58.8 39.1 34.8-43.9 72.8 37.2 33.5-41.3
   I(b) Acute myeloid leukemia 6.8 12.7 1.6 3.3 3.4 7.6 6.6 14.9 11.8 7.8 5.9-10.1 18.4 9.6 7.7-11.7
II Lymphomas and reticuloendothelial neoplasms 10.6 19.8 12.6 25.9 14.0 31.2 29.8 67.2 37.2 25.8 22.2-29.7 67.0 36.2 32.4-40.3
   II(a) Hodgkin lymphoma 0.8 1.5 1.4 2.9 4.4 9.8 16.4 37.0 6.6 4.8 3.3-6.7 23.0 12.9 10.6-15.5
   II(b,c,d) Non-Hodgkin lymphomas 9.6 17.9 11.2 23.1 9.6 21.4 13.0 29.3 30.4 20.8 17.6-24.4 43.4 23.0 20.0-26.2
III CNS & misc intracranial & intraspinal neoplasms 20.8 38.9 15.4 31.7 16.8 37.4 10.0 22.5 53.0 36.0 31.8-40.6 63.0 32.6 29.1-36.4
   III(a) Ependymomas and choroid plexus tumor 2.6 4.9 0.4 0.8 0.6 1.3 0.6 1.4 3.6 2.3 1.4-3.7 4.2 2.1 1.3-3.2
   III(b) Astrocytoma 8.4 15.7 7.6 15.7 8.2 18.3 4.6 10.4 24.2 16.6 13.7-19.8 28.8 15.0 12.7-17.7
   III(c) Intracranial and intraspinal embryonal tumors 5.2 9.7 3.4 7.0 2.8 6.2 1.2 2.7 11.4 7.6 5.7-9.8 12.6 6.4 4.9-8.2
   III(d) Other gliomas 3.4 6.4 3.2 6.6 4.6 10.2 2.8 6.3 11.2 7.8 5.9-10.1 14.0 7.4 5.8-9.4
IV Neuroblastoma and other peripheral nervous cell tumors 17.6 32.9 4.2 8.6 0.4 0.9 0.6 1.4 22.2 13.7 11.3-16.5 22.8 10.6 8.7-12.7
   IV(a) Neuroblastoma and ganglioneuroblastoma 17.6 32.9 4.2 8.6 0.4 0.9 0.4 0.9 22.2 13.7 11.3-16.5 22.6 10.5 8.6-12.6
V Retinoblastoma 9.2 17.2 0.2 0.4 0.2 0.4 0.0 0.0 9.6 5.7 4.2-7.6 9.6 4.3 3.2-5.7
VI Renal tumors 10.0 18.7 2.0 4.1 1.4 3.1 1.0 2.3 13.4 8.5 6.6-10.8 14.4 6.9 5.4-8.7
   VI(a) Nephroblastoma and other nonepithelial renal tumor 10.0 18.7 1.8 3.7 0.4 0.9 0.0 0.0 12.2 7.6 5.8-9.8 12.2 5.7 4.3-7.3
VII Hepatic tumors 3.8 7.1 0.2 0.4 0.4 0.9 1.0 2.3 4.4 2.7 1.7-4.1 5.4 2.6 1.7-3.8
   VII(a) Hepatoblastoma and mesenchymal tumors of liver 3.8 7.1 0.0 0.0 0.0 0.0 0.2 0.5 3.8 2.3 1.4-3.6 4.0 1.8 1.1-2.8
VIII Malignant bone tumors 1.0 1.9 4.2 8.6 9.4 20.9 9.6 21.6 14.6 10.7 8.3-13.4 24.2 13.4 11.1-16.0
   VIII(a) Osteosarcoma 0.0 0.0 2.0 4.1 6.2 13.8 5.4 12.2 8.2 6.1 4.4-8.2 13.6 7.6 5.9-9.6
   VIII(c) Ewing tumor and related sarcomas of bone 0.4 0.7 1.6 3.3 2.0 4.5 3.2 7.2 4.0 2.9 1.8-4.4 7.2 4.0 2.8-5.5
IX Soft tissue and other extraosseous sarcomas 8.0 15.0 5.4 11.1 7.8 17.4 9.0 20.3 21.2 14.5 11.8-17.5 30.2 15.9 13.5-18.7
   IX(a) Rhabdomyosarcoma 4.8 9.0 2.6 5.4 1.8 4.0 1.6 3.6 9.2 6.0 4.4-8.1 10.8 5.4 4.1-7.1
X Germ cell & trophoblastic tumors & gonadal neoplasms 3.8 7.1 2.4 4.9 5.0 11.1 12.0 27.1 11.2 7.7 5.8-10.0 23.2 12.6 10.4-15.1
   X(a) Intracranial and intraspinal germ cell tumor 0.4 0.7 0.6 1.2 2.0 4.5 0.8 1.8 3.0 2.2 1.2-3.6 3.8 2.1 1.2-3.2
   X(c) Malignant gonadal germ cell tumor 1.4 2.6 1.4 2.9 2.8 6.2 8.6 19.4 5.6 3.9 2.6-5.7 14.2 7.8 6.1-9.9
XI Other malignant epithelial neoplasms and malignant melanomas 1.4 2.6 2.2 4.5 10.8 24.1 33.8 76.2 14.4 10.5 8.2-13.2 48.2 27.0 23.7-30.7
   XI(b) Thyroid carcinoma 0.4 0.7 1.0 2.1 4.8 10.7 19.4 43.7 6.2 4.6 3.1-6.5 25.6 14.4 12.0-17.1
   XI(d) Malignant melanoma 0.4 0.7 0.0 0.0 0.0 0.0 1.6 3.6 0.4 0.2 0.0-0.9 2.0 1.1 0.5-2.0
XII Other and unspecified malignant neoplasms 0.4 0.7 0.4 0.8 0.2 0.4 0.4 0.9 1.0 0.7 0.2-1.6 1.4 0.7 0.3-1.5

Notes

  • Incidence data are provisional, November 2022.
  • Rates are per 1,000,000 children. Rates for 0-14 and 0-19 year age intervals are age-adjusted within these intervals to the 2000 US standard population, with 95% confidence intervals.
  • Rates based on fewer than 4 cases per year are unstable and should be used with caution.
  • Non-Hodgkin lymphomas, Burkitt, and miscellaneous lymphomas are grouped together under II(b,c,d).